Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Doxorubicin or Anti-estrogen in Metastatic Breast Cancer
NCT02648477Phase 2Completed
- Sponsor
- City of Hope
- Start
- Mar 2016
- Primary completion
- Apr 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in breast cancer (2 cohorts), sponsored by City of Hope. Primary endpoint: Overall Response Rate at 3 years. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02648477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02648477.